TG Therapeutics receives Orphan Drug designation for umbralisib from FDA
TG Therapeutics announced the FDA granted orphan drug designation to its phosphoinositide-3-kinase delta inhibitor, umbralisib (TGR-1202), for treatment of patients with all three types of marginal zone lymphoma: nodal, extranodal, and splenic MZL. April 15, 2019